We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Mar 2020 09:49

RNS Number : 7644F
4d Pharma PLC
11 March 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

4d pharma plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Link Fund Solutions Ltd

City and country of registered office (if applicable)

6th Floor, 65 Gresham Street, London EC2V 7NQ, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

10/03/2020

6. Date on which issuer notified (DD/MM/YYYY):

10/03/2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.96%

 

11.96%

109,493,842

Position of previous notification (if

applicable)

19.99%

 

19.99%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJL5BR07

13,091,131

 

11.96%

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Link Fund Solutions Ltd

11.96%

 

11.96%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

6th Floor, 65 Gresham Street, London EC2V 7NQ, United Kingdom

Date of completion

10/03/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFIFSAVRILLII
Date   Source Headline
21st Dec 20187:00 amRNSDirector/PDMR Shareholding
19th Dec 20187:00 amRNSDirector/PDMR Shareholding
13th Dec 20187:00 amRNSPDMR Dealings
12th Dec 20184:40 pmRNSSecond Price Monitoring Extn
12th Dec 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20187:00 amRNSTrading Statement
8th Nov 20187:00 amRNSClinical Update - Blautix Phase II study
8th Nov 20187:00 amGNW4D pharma plc Announces Clinical Update for Blautix Phase II Study
28th Sep 20187:00 amRNSInterim results
24th Sep 20187:00 amRNSClinical update and publication of studies
14th Aug 20187:00 amRNS4D asthma publication
30th Jul 20187:00 amRNSPublication - microbiota as HDAC inhibitors
27th Jun 20187:00 amRNS4D Presents at IHMC 2018
25th Jun 20184:40 pmRNSSecond Price Monitoring Extn
25th Jun 20184:35 pmRNSPrice Monitoring Extension
13th Jun 20187:00 amRNSMHRA and HPRA clear Blautix Phase II study
12th Jun 20184:51 pmRNSHolding(s) in Company
7th Jun 20187:00 amRNSClinical Collaboration Agreement
4th Jun 20187:00 amRNS4D Presents Phase Ib Clinical Data on Blautix
21st May 201812:08 pmRNSResult of AGM
21st May 20187:00 amRNSMRx0518 - Monotherapy trial approved
8th May 20187:00 amRNSClinical Update - Blautix IND
26th Apr 20187:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20187:00 amRNSFinal Results
21st Mar 20187:00 amRNSOncology candidate update
20th Feb 20187:00 amRNSAppointment of Joint Broker
28th Sep 20177:00 amRNSInterim results
5th Sep 201712:54 pmRNSHolding(s) in Company
24th Aug 20177:00 amRNSIssue of Equity
26th May 20171:59 pmRNSResult of AGM
17th May 20174:40 pmRNSSecond Price Monitoring Extn
17th May 20174:35 pmRNSPrice Monitoring Extension
3rd May 20177:00 amRNSAnnual Report and Notice of AGM
27th Apr 20177:00 amRNSFinal Results
18th Apr 20177:59 amRNSAppointment of Joint Broker
10th Mar 20174:37 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSClinical Update
13th Dec 20167:00 amRNSClinical Update
9th Nov 20164:40 pmRNSSecond Price Monitoring Extn
9th Nov 20164:35 pmRNSPrice Monitoring Extension
8th Nov 20164:40 pmRNSSecond Price Monitoring Extn
8th Nov 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20164:40 pmRNSSecond Price Monitoring Extn
19th Oct 20164:35 pmRNSPrice Monitoring Extension
30th Sep 20167:00 amRNSInterim results for the period ended 30 June 2016
27th Sep 201610:59 amRNSHolding(s) in Company
15th Sep 20164:40 pmRNSSecond Price Monitoring Extn
15th Sep 20164:35 pmRNSPrice Monitoring Extension
9th Sep 201611:58 amRNSHolding(s) in Company
22nd Aug 20167:00 amRNSClinical Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.